March 09, 2012 08:00 ET

Equity Research on Valeant Pharmaceuticals International and Elan Corp. plc - Drug Delivery Companies Up and Down

NEW YORK, NY--(Marketwire - Mar 9, 2012) - has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the Drug Delivery industry and are offering free analytical research on Valeant Pharmaceuticals International (NYSE: VRX) and Elan Corp. plc (NYSE: ELN). Register with us today at to have free access to these research reports.

The Drug Delivery industry has been mixed recently, as a number of factors have hindered and helped specific companies in different ways. As a result, some companies have been growing their operations through acquisitions, while others have divested themselves of certain assets in order to improve the financial positions. Get your free reports on Valeant Pharmaceuticals International and Elan Corp. plc at There is no commitment to join. is the Ultimate Trading Environment for investors. If you are considering owning Valeant Pharmaceuticals International and Elan Corp. plc then you should sign up for a free membership and our complimentary reports today at Over the last 5 years our returns outpaced any of the major indexes. Sign up today to find out what you are missing.

Several companies with operations in dermatology, such as Valeant Pharmaceuticals, have been performing well recently. Valeant made a number of acquisitions last year which are now contributing positively to its financials. The company reported 4th quarter revenue of $688.4 million, a significant improvement over the $514.6 million it earned during the same period last year. Valeant also managed to decrease its cost of goods sold for the quarter. Valeant Pharmaceuticals International report is accessible for free by registering today at

One company that has been having a challenging time as of late is Elan Corp. plc. Although the company has seen growth in sales of its Tysabri product, it recently posted a 4th quarter loss. The company has been taking corrective steps though, and announced that it expects to generate strong revenues in 2012 and adjusted EBITDA in excess of $200 million. Elan Corp. plc report is accessible for free by registering today at

The two Drug Delivery stocks research reports are available for free by signing up now on

Shine's Rooms is the brainchild of David Shine, a 13-year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting-edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.

To view our disclaimer, visit this link

Contact Information